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Relationship of the standard 
uptake value of 18F‑FDG‑PET‑CT 
with tumor‑infiltrating 
lymphocytes in breast tumors 
measuring ≥ 1 cm
Soeun Park1,3,6, Eun‑ki Min1,6, Soong June Bae1, Chihwan Cha1,4, Dooreh Kim1, 
Janghee Lee1,5, Yoon Jin Cha2, Sung Gwe Ahn1* & Joon Jeong1
Evidence suggests that tumor cells and tumor‑infiltrating lymphocytes (TILs) compete for glucose 
in the tumor microenvironment and that tumor metabolic parameters correlate with localized 
immune markers in several solid tumors. We investigated the relationship of the standardized 
uptake value (SUV) of 18F‑fluorodeoxyglucose positron emission tomography computed tomography 
(18F‑FDG‑PET‑CT) with stromal TIL levels in breast cancer. We included 202 patients who underwent 
preoperative 18F‑FDG‑PET‑CT and had a tumor measuring ≥ 1 cm. Maximum SUV (SUVmax) was 
determined using 18F‑FDG‑PET‑CT. Multiple logistic regression was used to identify factors related 
to high TIL levels (≥ 40%). All tumors were treatment naïve. A significant and weak correlation 
existed between continuous SUVmax and continuous TIL levels (p = 0.002, R = 0.215). Tumors with 
high SUVmax (≥ 4) had higher mean TIL levels than those with low SUVmax (< 4). In multivariable 
analysis, continuous SUVmax was an independent factor associated with high TIL levels; each 1‑unit 
increment in SUVmax corresponded to an odds ratio of 1.14 (95% confidence interval: 1.01–1.29) for 
high TIL levels. Our study implies that SUV is associated with TILs in breast cancer and provides clinical 
evidence that elevated glucose uptake by breast tumors can predict the immune system‑activated 
tumor micromilieu.
The tumor microenvironment (TME) is an ensemble of non-tumor cells including immune cells, fibroblasts, 
and endothelial  cells1 and affects tumor development and progression through dynamic interactions with cancer 
 cells2. Identification of TME interplays depending on the tumor’s metabolic activity has revealed that the TME 
regulates tumor  metabolism3. A previous study has reported that the demand for glucose is increased in tumor 
cells and tumor-specific immune cells, and this competition for glucose uptake between tumor cells and immune 
cells can directly influence cancer  progression4.
Tumor-infiltrating lymphocytes (TILs) are a cellular component of the immune system in the TME. Several 
clinical trials have reported the prognostic and predictive importance of TILs in breast cancer. In these trials, 
TIL levels have been highlighted as a biomarker for predicting treatment response to chemotherapy in patients 
with breast  cancer5–8. The studies also found that tumors with high TIL levels have shown favorable prognosis 
among triple negative breast cancer (TNBC) or human epidermal growth factor receptor-2 (HER2)-positive 
breast  cancer7,9–12. Furthermore, high TIL levels are associated with high-proliferative, high-grade, estrogen 
receptor (ER)-negative tumors and higher pathologic complete response (pCR)  rates8,13–17.
18F-fluorodeoxyglucose-positron emission tomography-computed tomography (18F-FDG-PET-CT) provides 
important tumor-related qualitative and quantitative information on cancer based on glucose  metabolism18. 
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For breast cancer, a high maximum standardized uptake value (SUVmax) is related to tumor aggressiveness, 
advanced stage, and poor  prognosis19–23.
To identify the relationship between tumor metabolic status and tumor immunogenicity, recent studies have 
reported the correlations between SUVmax and immune markers in gastric cancer, non-small cell lung cancer, 
and breast  cancer24–29. In this study, we aimed to explore the correlation between the SUVmax of 18F-FDG-PET-
CT and stromal TIL levels in breast cancer.
Results
Baseline characteristics. The characteristics of the 202 patients included in this study are summarized 
in Table 1. The median patient age was 53.2 years. Most tumors were invasive ductal carcinoma (86.1%) and 
showed favorable biology such as histological grade I or II (77.2%), nuclear grade 1 or 2 (66.3%), luminal/
HER2(−) (71.8%), and low Ki-67 labeling index (L.I.) (55.0%). More than half of the tumors had a small tumor 
burden; 58.4% tumors had T stage 1 and 73.3% tumors were node-negative. The median SUVmax was 4.68, and 
the median TIL level was 15%.
Tumor characteristics related to TIL levels. We evaluated the correlation between continuous TIL lev-
els and continuous SUVmax using Pearson’s correlation analysis (Fig. 1). There was a significant and weak cor-
relation between continuous SUVmax and continuous TILs (p = 0.002, Pearson’s r = 0.215).
Table 1.  Patient characteristics. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal 
growth factor receptor-2, TNBC triple-negative breast cancer, AR androgen receptor, SUV standard 
uptake value, TIL tumor-infiltrating lymphocytes. 1 Missing value. 2 HER2 positivity was defined as 3 + on 
immunohistochemistry or amplification on fluorescence in situ hybridization.
Number (%)
Age (years), median (range) 53.2 (24–87)
Histology
 Invasive ductal carcinoma 174 (86.1)












 I or II 156 (77.2)
 III 45 (22.3)
Nuclear grade1
 1 or 2 135 (66.3)
 3 65 (32.2)
ER positive 163 (80.7)
PR positive 137 (67.8)






  < 14% 111 (55.2)
  ≥ 14% 90 (44.6)
AR (%), mean (SD) 87.01 (± 25.25)
SUV max, median (range) 4.68 (0.63–18.54)
TIL (%), median (range) 15 (5–95)
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Next, we compared mean TILs according to tumor characteristics (Table 2). Invasive ductal carcinoma (IDC) 
showed significantly higher mean TIL levels than invasive lobular carcinoma or other histological cancer types. 
The mean TIL levels were higher in tumors with histological grade (HG) III than in those with HG I or II. Simi-
larly, mean TIL levels were higher in tumors with nuclear grade (NG) 3 than in those with NG 1 or 2. Among 
the subtypes, luminal/HER2(-) tumors showed the lowest mean TIL levels. When divided by Ki-67 L.I. of 14%, 
tumors with high Ki-67 L.I. showed higher mean TIL levels than those with low Ki-67 L.I. We also compared 
mean TIL levels based on the categorized SUVmax with a cutoff value of  420,30. Tumors with a high SUVmax 
value showed higher mean TIL levels than those with a low SUVmax value (p = 0.028, Mann–Whitney U test).
Predictive factors for tumors with high TIL levels. We identified factors predicting TIL levels ≥ 40% 
using logistic regression analysis (Table 3). In univariable analysis, the significant variables were age, HG, NG, 
tumor subtypes, Ki-67 L.I., androgen receptor (AR) percentage, and continuous SUVmax. Because the tumor 
subtypes were decided based on a combination of estrogen receptor (ER), progesterone receptor (PR), and HER2 
Figure 1.  Correlation between the continuous maximum standardized uptake value (SUVmax) and tumor-
infiltrating lymphocyte (TIL) levels.
Table 2.  Mean tumor-infiltrating lymphocyte levels (%) according to tumor characteristics. IDC invasive 
ductal carcinoma, ILC invasive lobular carcinoma, HER2 human epidermal growth factor receptor-2, TNBC 
triple-negative breast cancer, SUV standard uptake value, SD standard deviation. 1 Kruskal–Wallis test. 2 Mann–
Whitney U test. 3 Missing value.
N Mean (SD) p value
Histology1 0.001
 IDC 174 24.20 (± 21.98)
 ILC 17 11.27 (± 11.20)
 Others 11 13.64 (± 26.77)
T stage2 0.426
 1 118 21.03 (± 21.34)
 2–3 84 24.19 (± 22.65)
N stage2
 0 148 23.41 (± 23.37) 0.536
 1–3 54 19.85 (± 16.98)
Histologic grade2,3  < 0.001
 I or II 156 18.70 (± 19.68)
 III 45 35.74 (± 25.09)
Nuclear grade2,3  < 0.001
 1 or 2 136 17.54 (± 17.86)
 3 65 33.29 (± 25.99)
Subtypes1  < 0.001
 Luminal/HER2(−) 145 17.38 (± 15.90)
 HER2(+) 32 36.32 (± 27.97)
 TNBC 25 37.78 (± 29.58)
Ki-67 labeling index2,3 0.003
  < 14% 111 17.29 (± 17.45)
  ≥ 14% 90 28.21 (± 24.29)
SUVmax2 0.028
  < 4 85 18.33 (± 21.25)
  ≥ 4 117 25.33 (± 22.10)
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status, only tumor subtype was included in the multivariable model to avoid collinearity of variables. In multi-
variable analysis, tumor subtypes and continuous SUVmax remained an independent variable associated with 
high TIL levels, and NG was marginally significant (p = 0.050) for predicting high TIL levels. When the SUV-
max increased by 1 unit, the probability of high TIL levels increased by 14% (95% confidence interval [CI]: 
1.011–1.285, p = 0.032).
Additionally, to evaluate the predictive ability of continuous SUVmax for TIL levels ≥ 40%, we determined the 
area under the curve (AUC) using receiver operating characteristic (ROC) curves. The ROC curve for SUVmax 
in relation to TIL levels yielded an AUC of 0.673 (95% CI: 0.582–0.764, p = 0.001; Fig. 2).
Discussion
In this study, we found an association between TIL levels and SUVmax in breast cancer (≥ 1 cm). Tumors with 
a high SUVmax value showed a higher mean TIL level than those with a low SUVmax value and there was a 
correlation between continuous SUVmax and TIL level. In multivariable analysis, SUVmax was an independent 
factor for predicting tumors with high TIL levels.
Correlations between SUVmax and TIL levels have been previously reported in non-small cell lung cancer 
and gastric cancer. In non-small cell lung cancer, SUVmax was correlated with CD8(+) TILs as well as CD163(+) 
tumor-associated macrophages, FoxP3(+) Treg cells, and PD-1(+) and PD-L1(+)  cells24. In gastric cancer, SUV-
max showed a marginal association with CD3(+) lymphocytes and a significant association with FoxP3(+) Treg 
 cells25. In breast cancer, the relationship between SUVmax and TIL levels has been addressed in recent studies. 
Sasada et al. investigated this relationship using both whole-body positron emission tomography (PET) and 
dedicated breast PET (DbPET)29. SUVmax correlated with TILs in both whole-body PET and DbPET, and only 
DbPET was related to TIL levels after propensity score matching analysis. They suggested that DbPET could 
be more accurate in assessing fluorodeoxyglucose uptake in breast cancer, and their findings are in line with 
our finding that SUVmax is associated with TIL levels. Collectively, the abovementioned studies support our 
Table 3.  Predictive factors for tumors with high tumor-infiltrating lymphocyte levels. Bold font is used to 
also highlight statistically significant values. ANC absolute neutrophil count, ALC absolute lymphocyte count, 
ER estrogen receptor, HER-2 human epidermal growth factor receptor-2, IDC invasive ductal carcinoma, PR 
progesterone receptor, TNBC triple-negative breast cancer, OR odds ratio, CI confidence interval, AR androgen 
receptor, ILC invasive lobular carcinoma.
Univariable analysis Multivariable analysis
ORs (95% CIs) p value ORs (95% CIs) p value
Age 1.029 (0.997–1.061) 0.074 1.017 (0.982–1.054) 0.337
Histology
 IDC Ref 0.202
 ILC 0.209 (0.027–1.628) 0.135
 Others 0.335 (0.042–2.697) 0.304
T stage
 1 Ref
 2–3 1.540 (0.778–3.048) 0.216
N stage
 0 Ref
 1–3 0.824 (0.374–1.816) 0.631
Histologic grade
 I or II Ref
 III 4.873 (2.323–10.223)  < 0.001 1.508 (0.534–4.255) 0.438
Nuclear grade
 1 or 2 Ref
 3 4.375 (2.145–8.923)  < 0.001 2.248 (1.000–5.053) 0.050
ER( +) (Ref: ( −)) 0.234 (0.109–0.503)  < 0.001
PR( +) (Ref: ( −)) 0.258 (0.127–0.524)  < 0.001
HER2( +) (Ref: ( −)) 3.172 (1.496–6.722) 0.003
Subtypes
 Luminal/HER2( −) Ref  < 0.001
 HER2( +) 5.856 (2.472–13.873)  < 0.001 3.166 (1.218–8.229) 0.018
 TNBC 5.916 (2.316–15.112)  < 0.001 3.706 (1.329–10.340) 0.012
Ki-67 labeling 
index ≥ 14% (Ref: <14%) 3.922 (1.863–8.258)  < 0.001 1.512 (0.604–3.785) 0.377
AR (%) 0.984 (0.972–9.995) 0.005 1.001 (0.983–1.020) 0.879
SUVmax 1.211 (1.092–1.344)  < 0.001 1.140 (1.011–1.285) 0.032
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findings and suggest that SUVmax could have a potential role in assessing the immune system-activated tumor 
micromilieu.
In addition, these findings indicate that SUVmax can be a potential biomarker associated with immune-
targeting therapy. In the study conducted by Hirakata et al.26, there were significant associations between SUVmax 
and PD-L1(+) TIL levels and between SUVmax and TIL levels. Since PD-L1 expression in immune cells has 
already been used in clinical practice to determine the use of atezolizumab as an anti-PD-L1-targeting mono-
clonal antibody in metastatic breast  cancer31,32, it is worthwhile to address the predictive function of SUVmax 
in relation to the response of immune-check point inhibitors (ICIs).
Moreover, our previous genomic study revealed that Transforming growth factor (TGF) pathway genes, which 
attenuate the response to  ICIs33, were significantly downregulated in tumors with a high SUV  value34. Further, we 
found that the SUV signature was significantly associated with ICI responsiveness and improved overall survival 
in patients with urothelial cancer treated with ICIs. Taken together, our findings provide evidence that SUVmax 
can be assessed in terms of ICI responsiveness in breast cancer.
Our study has several limitations. First, this was a retrospective study conducted in a single institution, and 
there was a difference between patient characteristics, especially tumor subtypes. Because we excluded patients 
who received neoadjuvant chemotherapy, there were a small number of cases with more aggressive tumor types 
(HER2(+) or TNBC) and advanced disease. To overcome this, multivariable analysis was performed to demon-
strate the independent capability of SUVmax in predicting high TIL levels. Second, although we used previously 
reported cutoff values for TIL levels and SUVmax, there are no standard cutoff values. Third, more specific 
immune biomarkers such as PD-L1 or the subpopulations of TILs were not assessed. A more detailed analysis 
is needed to comprehensively understand the mechanism underlying the relationship between TIL levels and 
SUVmax. Lastly, survival analysis was not performed due to the short follow-up period. Assessment of clinical 
outcomes could be helpful in identifying the prognostic capability of this relationship. Despite these shortcom-
ings, our study has the advantage of enrolling the largest number of patients thus far.
In conclusion, we found associations between the SUVmax of 18F-FDG-PET-CT and stromal TIL levels in 
breast cancer. These results suggest that elevated glucose uptake in breast tumors can be used to predict the 
activation of the immune system in the TME. Further studies are warranted to comprehensively understand the 
interactions between the immune and metabolic systems in the TME and identify the clinical role of SUVmax 
of 18F-FDG-PET-CT in predicting TIL levels.
Methods
Patients. Between August 2016 and December 2017, we enrolled 202 patients with stage I-III breast cancer 
who underwent preoperative 18F-FDG-PET-CT followed by primary surgery at Gangnam Severance Hospital, 
Yonsei College of Medicine, South Korea. In these patients, we successfully evaluated the SUVmax values and 
stromal TIL levels. To circumvent the effect of chemotherapy on SUVmax values and TIL levels, patients who 
underwent preoperative chemotherapy were excluded. To address more clear relationship between SUVmax 
and stromal TIL levels by reducing the partial-volume effect of  PET35, we included only patients with tumors 
measuring ≥ 1 cm.
Clinical data on age at the time of surgery, HG, NG, tumor size, ER status, PR status, HER2 status, AR 
percentage, and Ki-67 L.I. were collected from the medical database. Tumors were classified according to the 
tumor–node–metastasis staging of the American Joint Committee on Cancer, 7th edition, and tumor grade was 
determined using the modified Scarf-Bloomer-Richardson grading  system36. The study was approved by the 
Institutional Review Board (IRB) of Gangnam Severance Hospital (Local IRB number: 2020-0950-001), which 
waived the requirement of informed consent due to the retrospective study design. The study was performed in 
accordance with good clinical practice guidelines and the Declaration of Helsinki.
Figure 2.  Area under the curve of the maximum standardized uptake value (SUVmax) predicting tumor-
infiltrating lymphocyte (TIL) levels ≥ 40%
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Assessment of TIL levels. TIL levels were measured as described in previous  studies37,38. A pathologist 
(Y.J.C.) performed hematoxylin and eosin staining to review the histological features of treatment-naïve surgical 
specimens. Stromal TIL levels were evaluated according to the standardized methodology proposed by the inter-
national TIL Working  Group11. The tumor area, defined by the presence of invasive tumor cells, was identified. 
All mononuclear cells including lymphocytes and plasma cells, but not polymorphonuclear leukocytes, were 
counted. The areas outside the tumor border, around the intraductal component, and around the normal lobules 
were excluded. Within the tumor border, areas showing crush artifacts and necrosis were also excluded. For each 
case, the average TIL level was measured using a representative section of the whole tumor, and the average level 
was reported as a percentage.
In this study, the cutoff value of high TIL level was set as 40%, which was used to analyze associations between 
TIL levels and pathological CR (pCR) or event-free survival in the NeoALTTO  study39.
18F‑FDG‑PET‑CT estimation. The procedure for 18F-FDG-PET-CT was the same as that previously 
 reported20. After at least 8 h of fasting, patients received an intravenous injection of 18F-FDG (0.14 MBq) in the 
arm contralateral to the primary tumor. Sixty minutes after injection of 18F-FDG, whole-body positron emis-
sion tomography scans were obtained using a Philips Allegro PET camera (Philips Medical Systems, Cleveland, 
OH, USA). During the scans, patients were placed in the supine position with their arms raised. The SUV was 
calculated by measuring the 18F-FDG uptake by the primary tumor in the region of interest using the following 
formula: SUV = (maximal radioactivity concentration in the region of interest)/(injected dose/patient’s weight 
(kg)). The SUV cutoff value of 4 was determined according to previous  studies20,30,34.
Statistical analysis. Pearson’s correlation coefficient was calculated to measure the correlation between 
continuous TIL levels and SUV. According to tumor characteristics, mean TILs levels were compared using the 
Mann–Whitney U test or Kruskal–Wallis test. The Kolmogorov–Smirnov test was used to test the normal dis-
tribution of TIL data. The distributions of nonparametric variables were compared using the Mann–Whitney U 
test or Kruskal–Wallis test. The clinicopathological factors associated with high TIL levels (≥ 40%) were analyzed 
using logistic regression analysis. Variables that showed a significant difference (p < 0.10) in univariate analysis 
were entered in multivariable analysis. To evaluate the ability of continuous SUVmax to predict TIL levels ≥ 40%, 
we determined the AUC using ROC curves. All statistical tests were two tailed, and p < 0.05 was considered 
statistical significant. All statistical analyses were performed using SPSS, version 26.0 (SPSS, Chicago, IL, USA).
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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